

BELLA WANG

Counsel

Fangda Partners

+86 21 2208 5935

Bella.wang@fangdalaw.com



PRACTICE AREAS

MS. WANG SPECIALIZES IN CORPORATE AND COMMERCIAL LAW, INCLUDING M&A, PRIVATE EQUITY AND REGULATORY AFFAIRS. SHE HAS A STRONG DEAL RECORD IN THE PHARMA, LIFE SCIENCE AND GENERAL INDUSTRY SECTORS.

REPRESENTATIVE MATTERS AND CASES

- Represented AnHeart Therapeutics in granting a license to Innovent Biologics on the joint development and commercialization of AnHeart's major drug candidate, Taltrectinib
- Represented MitrAssist, a leading clinical stage medical device company offering innovative treatment for mitral regurgitation, in obtaining a license for heart-valve related technology and cooperation project
- Represented AstraZeneca in obtaining exclusive promotion rights from a leading foreign pharma company
- Represented AstraZeneca in granting to BioKangtai the exclusive license in China to AZD1222, an adenovirus vector-based COVID-19 vaccine
- Represented TopRidge Pharma in its in-license of the Sputnik-V vaccine developed in Russia
- Represented Eddingpharm in its pre-IPO reorganization and IPO on the main board of the Hong Kong Stock Exchange
- Represented Assembly Bio, Biogen, Cordis, CStone, Zai Lab, AnHeart, VISEN Pharmaceuticals and Virogin Biotech in general legal and compliance affairs, covering R&D projects, clinical trials, product distribution, product promotion, PAP, etc.
- Represented Sinopharm Capital in its equity investment transactions in the biotech and healthcare industries

- Represented Virogin Biotech in its Series C and Series D1 financing
- Represented IDG in its equity investment in the innovative online healthcare platform WEIMAI
- Represented BVCF in its equity investments in biotech companies
- Represented Covestro AG in acquiring a leading thin-film company in China
- Represented Wacker in its acquisition of a majority interest in a PRC company and in its cooperation with the PRC shareholders in the joint venture
- Represented Mount Kellett (now Fortress Investment) in its equity investment in and investment exit from a PRC real property brokerage company
- Represented E-Shang Redwood in its acquisitions and disposals of logistics property asset projects in China
- Represented LOGOS Logistics in its acquisitions of logistics property assets in China
- Represented City Developments Limited in its acquisition of property assets in China
- Represented Jingrui Holdings (01862.HK) in its joint venture projects with a leading US fund acquiring property in China
- Represented Johnson Matthey in its general legal and compliance affairs

OTHER INFORMATION

Education

- Boston University School of Law, LL.M. (2014)
- Shanghai University of Finance and Economics, School of Law, LL.B. (2011)

Professional Qualification

- Admitted to practice in the PRC

Professional Background

Ms. Wang joined Fangda as an associate in 2018. Before joining the firm, she worked for four years at another reputable law firm.